7Baggers
 Morgan Stanley Downgrades TScan Therapeutics(TCRX.US) to Hold Rating  富途牛牛 Fri, 14 Nov 2025 01:31:00 GMT
 TScan Therapeutics Reports Increased Revenue Amid Rising Losses  TipRanks Thu, 13 Nov 2025 04:27:49 GMT
 Tscan Therapeutics earnings beat by $0.06, revenue topped estimates  Investing.com Nigeria Thu, 13 Nov 2025 00:49:36 GMT
 Published on: 2025-11-12 17:29:17  newser.com Wed, 12 Nov 2025 23:29:17 GMT
 Tscan Therapeutics earnings beat by $0.06, revenue topped estimates  Investing.com Wed, 12 Nov 2025 22:43:11 GMT
 TScan Therapeutics reports Q3 EPS (28c), consensus (33c)  TipRanks Wed, 12 Nov 2025 12:35:08 GMT
 TScan Therapeutics Q3 revenue jumps  MarketScreener Wed, 12 Nov 2025 12:18:25 GMT
 using data filters to optimize entry into tscan therapeutics inc.  newser.com Tue, 11 Nov 2025 05:10:26 GMT
 is tscan therapeutics inc. stock attractive for etfs - cpi data & ai driven price forecasts  Fundação Cultural do Pará Thu, 06 Nov 2025 09:24:28 GMT
 tscan therapeutics (tcrx) projected to post earnings on tuesday  MarketBeat Wed, 05 Nov 2025 16:18:03 GMT
 Barclays Reaffirms Their Buy Rating on TScan Therapeutics (TCRX)  The Globe and Mail Wed, 05 Nov 2025 08:17:06 GMT
 Biotech firm TScan slashes jobs, extends cash runway amid strategic realignment  The Business Journals Tue, 04 Nov 2025 19:09:00 GMT
 tscan therapeutics (tcrx) analyst update: needham lowers price t  GuruFocus Tue, 04 Nov 2025 11:10:30 GMT
 BTIG downgrades Tscan Therapeutics stock to Neutral on program delays  Investing.com Tue, 04 Nov 2025 08:00:00 GMT
 TScan Therapeutics downgraded to Neutral from Buy at BTIG  TipRanks Tue, 04 Nov 2025 08:00:00 GMT
 TScan Therapeutics Shares Fall After BTIG Research Downgrade  MarketScreener Tue, 04 Nov 2025 08:00:00 GMT
 BTIG Research Downgrades TScan Therapeutics to Neutral From Buy  MarketScreener Tue, 04 Nov 2025 08:00:00 GMT
 tscan to focus on heme program, cuts workforce by 30% amid fda progress  Investing.com Nigeria Tue, 04 Nov 2025 03:02:47 GMT
 tscan lays off 30% of workforce, halts solid tumor tcr trial  Fierce Biotech Mon, 03 Nov 2025 13:25:00 GMT
 TScan Therapeutics to reduce workforce by 30%  TipRanks Mon, 03 Nov 2025 11:54:14 GMT
 TScan Therapeutics Reaches Agreement with FDA on Pivotal  GlobeNewswire Mon, 03 Nov 2025 11:30:00 GMT
 TScan Therapeutics Shifts Focus to Hematologic Malignancies  TipRanks Mon, 03 Nov 2025 08:00:00 GMT
 TScan to focus on heme program, cuts workforce by 30% amid FDA progress  Investing.com UK Mon, 03 Nov 2025 08:00:00 GMT
 published on: 2025-11-02 02:32:35  newser.com Sun, 02 Nov 2025 07:32:35 GMT

Tscan Therapeutics Inc
(NASDAQ:TCRX) 

TCRX stock logo

TScan Therapeutics is a biopharmaceutical company focused on the development of immunotherapy treatments for cancer.

Founded: 2018
CEO: David Southwell  
Sector:
Industry:

Share this website to your friends